Literature DB >> 16755546

Repeated measures analyses of dose timing of antiretroviral medication and its relationship to HIV virologic outcomes.

Honghu Liu1, Loren G Miller, Carol E Golin, Ron D Hays, Tongtong Wu, Neil S Wenger, Andrew H Kaplan.   

Abstract

Medication adherence is a critical predictor of the effectiveness of antiretroviral medications in the treatment of HIV/AIDS. Studies of adherence, however, have focused primarily on the per cent of prescribed doses taken (per cent adherence). In the Adherence and Efficacy of Protease Inhibitor Therapy study, we collected detailed adherence data including dose timing information as well as data regarding patients' virologic responses. For 48 weeks, adherence data and virologic outcomes were collected every 4 weeks, and demographics and other measures were collected at baseline and at weeks 8, 24, and 48. We constructed eight different dose timing error (DTE) measures and evaluated their associations with virologic outcomes using longitudinal analyses. Repeated measures mixed effect models were fitted to evaluate the predicting power of each of the DTE measures. Among 52 036 electronically measured doses obtained from 122 patients, DTE measures significantly predicted virologic outcomes. Of the eight different DTE measures, the six DTE measures were significantly predictive of virologic outcomes even after controlling for per cent adherence. In conclusion, we identified several measures of DTE that explain HIV virologic outcomes not captured by traditional adherence measures. Investigations of adherence to antiretrovirals would benefit from measuring not only per cent adherence but dose timing adherence. Copyright (c) 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16755546     DOI: 10.1002/sim.2592

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  8 in total

1.  Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.

Authors:  Ziad El-Khatib; Anna Mia Ekstrom; Johanna Ledwaba; Lerato Mohapi; Fatima Laher; Alan Karstaedt; Salome Charalambous; Max Petzold; David Katzenstein; Lynn Morris
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

2.  A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV.

Authors:  Brent A Moore; Marc I Rosen; Yan Wang; Jie Shen; Karen Ablondi; Anna Sullivan; Mario Guerrero; Lisa Siqueiros; Eric S Daar; Honghu Liu
Journal:  AIDS Behav       Date:  2015-06

3.  A DYNAMIC BAYESIAN NONLINEAR MIXED-EFFECTS MODEL OF HIV RESPONSE INCORPORATING MEDICATION ADHERENCE, DRUG RESISTANCE AND COVARIATES().

Authors:  Yangxin Huang; Hulin Wu; Jeanne Holden-Wiltse; Edward P Acosta
Journal:  Ann Appl Stat       Date:  2011       Impact factor: 2.083

4.  Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence.

Authors:  D M Evon; D A Esserman; J E Bonner; T Rao; M W Fried; C E Golin
Journal:  J Viral Hepat       Date:  2013-02-25       Impact factor: 3.728

Review 5.  HIV treatment adherence, drug resistance, virologic failure: evolving concepts.

Authors:  Jean B Nachega; Vincent C Marconi; Gert U van Zyl; Edward M Gardner; Wolfgang Preiser; Steven Y Hong; Edward J Mills; Robert Gross
Journal:  Infect Disord Drug Targets       Date:  2011-04

6.  Importance of dose timing to achieving undetectable viral loads.

Authors:  Christopher J Gill; Lora L Sabin; Davidson H Hamer; Xu Keyi; Zhang Jianbo; Tao Li; Wan-Ju Wu; Ira B Wilson; Mary Bachman Desilva
Journal:  AIDS Behav       Date:  2009-04-08

7.  Adherence during antiviral treatment regimens for chronic hepatitis C: a qualitative study of patient-reported facilitators and barriers.

Authors:  Donna M Evon; Carol E Golin; Jason E Bonner; Catherine Grodensky; Jennifer Velloza
Journal:  J Clin Gastroenterol       Date:  2015 May-Jun       Impact factor: 3.062

8.  Antiretroviral dynamics determines HIV evolution and predicts therapy outcome.

Authors:  Daniel I S Rosenbloom; Alison L Hill; S Alireza Rabi; Robert F Siliciano; Martin A Nowak
Journal:  Nat Med       Date:  2012-09       Impact factor: 53.440

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.